Product Program year 2021 Source: CMS Open Payments

Flumist Quadrivalent

Biological Respiratory

NDC 66019-308-10

Open in the dashboard

General payments

$2,278,271

406 payments

Research payments

$0

0 payments

Through program year 2021, $2,278,271 in general payments and $0 in research payments were reported against Flumist Quadrivalent (Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2021 General $2,278,271 406

Breakdown

Who paid General payments · program year 2021
  1. AstraZeneca Pharmaceuticals LP $2,278,271 406 payments
Top recipients General payments · program year 2021
  1. Univ Of Mi Hospitals & Hlth Ctrs Teaching hospital · MI $2,269,400 100% · 3 payments
  2. Ravi Jhaveri Pediatric Infectious Diseases · Chicago, IL $2,100 <1% · 1 payment
  3. Alan Epstein Rheumatology · Philadelphia, PA $92 <1% · 1 payment
  4. Maurice Chianese Pediatrics · Lake Success, NY $58 <1% · 3 payments
  5. Celia Escobar Pediatrics · New Hyde Park, NY $58 <1% · 3 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Pediatrics $4,705 53% · 255 practitioners
  2. Pediatric Infectious Diseases Pediatrics $2,124 24% · 2 practitioners
  3. Nurse Practitioner, Pediatrics Nurse Practitioner $359 4% · 23 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $283 3% · 18 practitioners
  5. Adolescent Medicine Pediatrics $247 3% · 15 practitioners

The top 5 of 30 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. Michigan $2,269,703 100% · 24 recipients
  2. Illinois $2,129 <1% · 3 recipients
  3. New York $1,240 <1% · 43 recipients
  4. Tennessee $1,067 <1% · 62 recipients
  5. California $510 <1% · 26 recipients

The top 5 of 26 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

406 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record